本帖最后由 老马 于 2012-1-13 21:20 编辑
' N& s6 r h- ^
; P" }2 K, N5 H5 {爱必妥和阿瓦斯丁的比较/ D9 `3 k3 r$ y8 j" |8 N
, W( M' m' [7 r9 q/ h
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" U8 N5 Z4 K4 ?
- n- f' h5 d" I) P
! L4 ?( j2 s& ~$ p
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
( `; U. f( A# L$ }- G5 m==================================================
/ _; `3 z; F4 N9 N5 GOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
5 y% x. e6 i( ^0 nPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. p8 I2 V w- ~9 l
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.9 S! Q# B+ f7 S1 a3 a Y% j& w
|